Involvement of gamma-aminobutyric acid in the control of GTH-1 and GTH-2 secretion in male and female rainbow trout.
The potential role of the neurotransmitter gamma-aminobutyric acid (GABA) in the control of the secretion of the two pituitary fish gonadotropins (GTH-1 and GTH-2) was investigated in male and female rainbow trout (Oncorhynchus mykiss). The presence of glutamate decarboxylase-positive fibers in the neurohypophyseal digitations adjacent to the gonadotropic cells was demonstrated by means of double immunohistochemistry, providing a morphofunctional support for potential GABA-gonadotropin interactions in both sexes. In spermiating males, in vivo treatment with GABA did not affect basal gonadotropin release, but stimulated GTH-1 release when coadministered with a gonadotropin-releasing hormone analogue (GnRHa), and potentiated GnRHa-stimulated GTH-2 release. In vitro, using dispersed pituitary cells, GABA stimulated basal GTH-1 and GTH-2 secretion, in a dose-dependent manner, and potentiated salmon GnRH effect on both hormones. In mature females, GABA induced in vivo a strong elevation of plasma GTH-2 levels after 2- 6 h of injection, but had no effect in vitro. GABA treatment in vivo was also stimulatory in recrudescent females, slightly increasing plasma GTH-2 levels in both saline- and GnRHa-treated fish (GnRHa alone has no effect at this stage). Immature fish were unresponsive to GABA/GnRHa treatments but, after steroid implantation [testosterone (T) or estradiol] for 13 days, injection of GABA stimulated GTH-2 release in vivo (also GTH-1 slightly in T-implanted fish). In conclusion, GABA has an overall stimulatory action on GTH-1 and GTH-2 secretion in rainbow trout, which depends on the sex and the reproductive stage of the fish. The stimulatory action of GABA might be exerted, at least in part, directly onto the gonadotropes, as it stimulates basal and GnRH-induced GTH-1 and GTH-2 secretion from dispersed pituitary cells.
Mañanos
E L
EL
Endocrinologie Moléculaire de la Reproduction, UPRES-A CNRS 6026, Rennes, France.
Anglade
I
I
Chyb
J
J
Saligaut
C
C
Breton
B
B
Kah
O
O
D000818:Animals; D002478:Cells, Cultured; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005968:Glutamate Decarboxylase / Q000032:analysis; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000494:pharmacology; D006065:Gonadotropins, Pituitary / Q000378:metabolism*; D007150:Immunohistochemistry; D008297:Male; D017686:Oncorhynchus mykiss / Q000502:physiology*; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism*; D010904:Pituitary Gland, Posterior / Q000201:enzymology; D013739:Testosterone / Q000008:administration & dosage / Q000494:pharmacology; D020888:Vigabatrin / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000502:physiology*
D004343:Drug Implants; D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004958:Estradiol; D005680:gamma-Aminobutyric Acid; D005968:Glutamate Decarboxylase; D020888:Vigabatrin; C058987:5-oxo-pro-his-trp-ser-tyr-gly-trp-leu-pro-glynh2